EE195 Quantifying the Avoided Costs of a Switch to Ofatumumab From Low/Moderate Efficacy Disease Modifying Therapies in Patients With Relapsing-Remitting Multiple Sclerosis in Colombia
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.464
https://www.valueinhealthjournal.com/article/S1098-3015(23)03594-5/fulltext
Title :
EE195 Quantifying the Avoided Costs of a Switch to Ofatumumab From Low/Moderate Efficacy Disease Modifying Therapies in Patients With Relapsing-Remitting Multiple Sclerosis in Colombia
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03594-5&doi=10.1016/j.jval.2023.09.464
First page :
Section Title :
Open access? :
No
Section Order :
12488